NCT00002228已完成2 期
A Phase II Evaluation of the Safety, Plasma Pharmacokinetics, and Antiviral Activity of T-20 Administered to HIV-1 Positive Adults By Continuous Subcutaneous Infusion or Subcutaneous Injection
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Trimeris
- 入组人数
- 78
- 试验地点
- 21
研究概览
简要总结
The purpose of this study is to see if it is safe and effective to give T-20 to HIV-positive adults. T-20 is an anti-HIV drug.
详细描述
Patients are randomly placed into 1 of 6 groups: 4 dose levels of T-20 are given by subcutaneous infusion and 2 by subcutaneous injection. The entire study lasts 7 weeks; including a 2-week screening period, followed by 28 days of treatment and 1 week of follow-up.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Any antiretroviral agent, provided the regimen has not changed within 6 weeks of the screening visit.
- •Antibiotics for bacterial infections.
- •Prophylactic medications for P. carinii pneumonia and for M. avium, including azithromycin.
- •Medications for symptomatic treatment such as antipyretics, analgesics, and antiemetics.
- •Patients must have:
- •HIV-1 seropositive status.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •Concurrent neoplasm (except for basal cell carcinoma of the skin, in situ carcinoma of the cervix, and non-disseminated stable Kaposi's sarcoma).
- •Concurrent Medication:
- •Patients must not be taking any concurrent antiretroviral therapy (for at least 2 weeks prior to baseline) or the patient is to be on a stable antiretroviral regimen which has not changed for at least 6 weeks prior to baseline.
- •Treatment with any of the following:
- •immunomodulators, biological response modifiers, chemotherapy that cannot be discontinued for the duration of the study, astemizole, terfenadine, cisapride, triazolam, midazolam, rifampin, clarithromycin, or an investigational drug within 30 days prior to the initial visit.
- •Patients with the following prior conditions are excluded:
- •Evidence of active opportunistic infections, or unexplained temperature greater than or equal to 38.5 Celsius for 7 consecutive days within 30 days prior to screening visit.
- •Chronic diarrhea (defined as greater than 3 liquid stools per day which persists for 15 days) within 30 days prior to screening visit.
- •Diagnosis of hemophilia or other clotting disorders.
- •Prior Medication:
- •- Prior treatment with an HIV vaccine.
- •Prior Treatment:
- •Major organ allograft.
- •Risk Behavior:
- •Evidence of substance abuse or addiction that, in the opinion of the investigator, may interfere with the patient's ability to comply with the dosing schedule and protocol evaluations.
研究者
研究点 (21)
Loading locations...
相似试验
已完成
2 期
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected AdultsHIV InfectionsNCT00002239Hoffmann-La Roche68
已完成
1 期
Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African AdultsHIV InfectionsNCT00123968National Institute of Allergy and Infectious Diseases (NIAID)326
已完成
2 期
Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian PatientsParkinson DiseaseNCT02763137IRCCS San Raffaele Roma18
已完成
2 期
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected PatientsHIV InfectionsNCT00002234Gilead Sciences25
已完成
1 期
Safety of an HIV DNA Vaccine Given to HIV Uninfected AdultsHIV InfectionsNCT00043511National Institute of Allergy and Infectious Diseases (NIAID)30